Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aurolab Procoat (and its higher-concentration variant, Aurolab Procoat Plus) is an ophthalmic viscosurgical device (OVD) developed by Aurolab. It is a sterile, preservative-free, isotonic, and pyrogen-free viscoelastic solution containing a combination of sodium hyaluronate and chondroitin sulfate. Aurolab Procoat contains 2% w/v sodium hyaluronate and 2% w/v chondroitin sulfate, while Procoat Plus contains 3% w/v sodium hyaluronate and 4% w/v chondroitin sulfate. This dual-action formulation combines the protective, tissue-coating advantages of a dispersive agent (provided by chondroitin sulfate) with the space-maintaining, cohesive benefits of sodium hyaluronate. It is indicated as a surgical aid in anterior segment ophthalmic procedures, including cataract extraction, intraocular lens (IOL) insertion, glaucoma surgery, and corneal transplant/retinal attachment surgery. By coating the corneal endothelium and maintaining the depth of the anterior chamber, it protects intraocular tissues from mechanical trauma during surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aurolab Procoat.